Novo Nordisk A/S

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial (2025) Mahaffey KW, Tuttle KR, Arici M, Baeres FM, Bakris G, Charytan DM, Cherney DZ, et al. Journal article Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6 (2025) Apperloo EM, Cherney DZ, Kuhlman AB, Mann JF, Rasmussen S, Rossing P, Tuttle KR, et al. Journal article Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial (2024) Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW, Mann JF, et al. Journal article Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (2024) Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, Baeres FM, et al. Journal article Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024) Mann JF, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, et al. Journal article Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial (2024) Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, et al. Journal article Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial (2023) McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JF, Marx N, Mulvagh SL, et al. Journal article Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2022) Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JF, et al. Journal article Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis (2021) Mann J, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, Vilsboll T, et al. Journal article Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (2021) Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann J, Pratley R, Raz I, et al. Journal article